InflaRx (NASDAQ:IFRX – Get Free Report) and TScan Therapeutics (NASDAQ:TCRX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.
Profitability
This table compares InflaRx and TScan Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InflaRx | N/A | -53.56% | -43.02% |
| TScan Therapeutics | -1,655.35% | -108.72% | -54.47% |
Institutional and Insider Ownership
42.4% of InflaRx shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 6.2% of TScan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| InflaRx | $30,000.00 | 7,663.24 | -$51.63 million | ($0.58) | -2.69 |
| TScan Therapeutics | $10.32 million | 1.82 | -$129.77 million | ($0.91) | -0.30 |
InflaRx has higher earnings, but lower revenue than TScan Therapeutics. InflaRx is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
InflaRx has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for InflaRx and TScan Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InflaRx | 1 | 2 | 5 | 1 | 2.67 |
| TScan Therapeutics | 1 | 5 | 2 | 0 | 2.12 |
InflaRx currently has a consensus target price of $7.43, indicating a potential upside of 376.19%. TScan Therapeutics has a consensus target price of $2.67, indicating a potential upside of 863.04%. Given TScan Therapeutics’ higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than InflaRx.
Summary
InflaRx beats TScan Therapeutics on 11 of the 15 factors compared between the two stocks.
About InflaRx
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
About TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.
